8-K

XOMA CORPORATION

Date: April 30, 2024

/s/ THOMAS BURNS

Thomas Burns

Senior Vice President, Finance and Chief Financial Officer

0001193125-24-123689.txt : 20240430 0001193125-24-123689.hdr.sgml : 20240430 20240430073034 ACCESSION NUMBER: 0001193125-24-123689 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240429 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XOMA Corp CENTRAL INDEX KEY: 0000791908 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 522154066 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39801 FILM NUMBER: 24894053 BUSINESS ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-204-7239 MAIL ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: XOMA LTD /DE/ DATE OF NAME CHANGE: 19990107 FORMER COMPANY: FORMER CONFORMED NAME: XOMA CORP /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 d798315d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): April 29, 2024

XOMA CORPORATION

(Exact Name of Registrant as Specified in Charter)


DELAWARE	001-39801	52-2154066
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

2200 Powell Street, Suite 310, Emeryville, California 94608

(Address of Principal Executive Offices) (Zip Code)

(510) 204-7200

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class:	Trading symbol(s):	Name of each exchange on which registered:
Common Stock, $0.0075 par value	XOMA	The Nasdaq Global Market
8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share	XOMAP	The Nasdaq Global Market
Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)	XOMAO	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events.

On April 29, 2024, XOMA Corporation (“XOMA”), through its wholly-owned subsidiary, XOMA (US) LLC (the “Company”), entered into a Traditional Royalty Purchase Agreement with Daré Bioscience, Inc. (“Daré”) (the “TRPA”) and a Synthetic Royalty Purchase Agreement with Daré (together with the TRPA, the “Purchase Agreements”).

Pursuant to the terms of the Purchase Agreements, the Company paid $22,000,000 in cash to Daré in consideration for the sale of (a) 100% of all remaining royalties related to XACIATO^™ not already subject to the royalty-backed financing agreement Daré entered into in December 2023 and net of payments owed by Daré to upstream licensors, which equates to royalties ranging from low to high single digits, and of all potential commercial milestones related to XACIATO^™ that are payable to Daré under that certain Exclusive License Agreement by and between Daré and Organon International GMBH, dated March 31, 2022, as amended; (b) a 4% synthetic royalty on net sales of OVAPRENE^®and a 2% synthetic royalty on net sales of Sildenafil Cream, 3.6%, which will decrease to 2.5% and 1.25%, respectively, upon XOMA achieving a pre-specified return threshold; and (c) a portion of Daré’s right to a certain milestone payment that may become payable to Daré under that certain License Agreement between Daré and Bayer HealthCare LLC, dated January 10, 2020. The Purchase Agreements also provide for certain milestone payments from the Company to Daré upon achieving a pre-specified return threshold, subject to the terms of the Purchase Agreements.

The foregoing description of the Purchase Agreements does not purport to be complete and is qualified in its entirety by reference to the complete text of the Purchase Agreements.

On April 30, 2024, the Company issued a press release announcing the transactions described herein, a copy of which is attached hereto as Exhibit 99.1.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

99.1		Press Release, dated April 30, 2024

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

-3-

EX-99.1 2 d798315dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

XOMA Adds Economic Interests in Three First-in-Category Assets

to its Royalty and Milestone Portfolio Including XACIATO^™ (clindamycin phosphate) Vaginal Gel 2%

Organon, a global women’s healthcare company, initiated XACIATO^™ commercial activities in the fourth quarter of 2023

XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women’s health assets: Ovaprene^®, an investigational potential first-in-category Phase 3 hormone-free monthly intravaginal contraceptive, and Sildenafil Cream, 3.6%, a potential first-in-category Phase 3-ready candidate for female sexual arousal disorder

Bayer HealthCare holds the exclusive rights to U.S. commercialization of Ovaprene^®

XOMA provided $22 million upfront as non-dilutive royalty capital solution to Daré Bioscience

EMERYVILLE, Calif., April 30, 2024 (GLOBE NEWSWIRE) – XOMA Corporation (NASDAQ: XOMA) announced today it has acquired an economic interest in three women’s health assets - XACIATO^™ (clindamycin phosphate) vaginal gel 2%, Ovaprene^®, and Sildenafil Cream, 3.6% - from Daré Bioscience, Inc., for an upfront payment of $22 million. XACIATO^™ is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial vaginosis (BV) in females 12 years of age and older. In 2022, Daré entered into a license agreement with Organon, which initiated XACIATO^™ commercial marketing activities in the fourth quarter of 2023.

“XACIATO^™, an important therapy, becomes the fifth commercial asset in XOMA’s royalty portfolio, and our royalty monetization transaction with Daré also adds two first-in-category Phase 3 royalty assets that have the potential to create additional value for our shareholders. Each of the three assets represents a meaningful advance in the women’s health category that has typically been under-represented and has significant growth potential,” stated Brad Sitko, Chief Investment Officer at XOMA. “XOMA structured an attractive, non-dilutive royalty capital solution that provides Daré with additional financial resources to advance its pipeline through key catalysts and aligns with its stockholders, enabling them to participate in the future value created by XACIATO^™, Ovaprene^®, and Sildenafil Cream.”

Under the terms of the agreement, XOMA will receive the remaining royalties related to XACIATO^™ not already included in Daré’s December 2023 royalty-backed financing agreement, which equates to low- to high-single digit royalties on net sales. XOMA also is entitled to potential milestone payments based on the commercial success of XACIATO. Additionally, XOMA has acquired an interest in a potential milestone and a low single-digit synthetic royalty on Ovaprene^®, as well as a low single-digit synthetic royalty on Sildenafil Cream, 3.6%. Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Daré.

Advisors

Gibson, Dunn & Crutcher LLP served as XOMA’s legal advisor, while Daré was advised by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. TD Cowen, a division of TD Securities, acted as exclusive financial advisor to Daré.

About XACIATO^™ (clindamycin phosphate) vaginal gel 2%

XACIATO vaginal gel is a prescription medicine used to treat bacterial vaginal infections in females 12 years of age and older, which is under a global license agreement with Organon. For more information, including important safety information, please visit www.xaciato.com.

About Ovaprene^®

Ovaprene^® is a novel investigational hormone-free monthly intravaginal contraceptive designed to be an easy-to use monthly option and prevent pregnancy by releasing a locally acting, non-hormonal agent, which impedes sperm motility, and physically blocks sperm from entering the cervical canal with its unique knitted polymer barrier. The novel combination of these complementary approaches has the potential to produce efficacy consistent with existing short-acting hormone birth control options (pills, patches, vaginal ring), without the use of hormones. U.S. commercial rights to Ovaprene^® are under a license agreement with Bayer.

About Sildenafil Cream, 3.6%

Sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra^® for the treatment of erectile dysfunction in men. Sildenafil Cream is an investigational, proprietary cream formulation of sildenafil designed for topical administration to the vulvar-vaginal tissue on demand to increase genital blood flow and provide improvements in the female genital arousal response, while avoiding systemic side effects observed with oral formulations of sildenafil.

About XOMA Corporation

XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow the Company on LinkedIn.

Forward-Looking Statements/Explanatory Notes

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA and other developments related to XACIATO^™, Ovaprene^®, and Sildenafil Cream, 3.6%. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, and our third-party licensees will not be able to market them. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA’s most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA’s prospects. Any forward-looking statement in this press release represents XOMA’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except VABYSMO^® (faricimab), OJEMDA^™ (tovorafenib), XACIATO^™ (clindamycin phosphate) vaginal gel 2%, IXINITY^® [coagulation factor IX (recombinant)], and DSUVIA^® (sufentanil sublingual tablet), are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.


XOMA Investor Contact		XOMA Media Contact
Juliane Snowden		Kathy Vincent
XOMA Corporation		KV Consulting & Management
+1 646-438-9754		+1 310-403-8951
juliane.snowden@xoma.com		kathy@kathyvincent.com

###

EX-101.SCH 3 xoma-20240429.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 xoma-20240429_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 xoma-20240429_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Series A Preferred Stock [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series B Preferred Stock [Member] EX-101.PRE 6 xoma-20240429_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g798315g0430124621865.jpg GRAPHIC begin 644 g798315g0430124621865.jpg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htm IDEA: XBRL DOCUMENT

Document and Entity Information	Apr. 29, 2024
Document And Entity Information [Line Items]
Entity Registrant Name	XOMA Corp
Entity Incorporation State Country Code	DE
Amendment Flag	false
Entity Central Index Key	0000791908
Document Type	8-K
Document Period End Date	Apr. 29, 2024
Entity File Number	001-39801
Entity Tax Identification Number	52-2154066
Entity Address, Address Line One	2200 Powell Street
Entity Address, Address Line Two	Suite 310
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	(510)
Local Phone Number	204-7200
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	Common Stock, $0.0075 par value
Trading Symbol	XOMA
Security Exchange Name	NASDAQ
Series A Preferred Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share
Trading Symbol	XOMAP
Security Exchange Name	NASDAQ
Series B Preferred Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)
Trading Symbol	XOMAO
Security Exchange Name	NASDAQ

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 4 23 1 false 3 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode, dei:EntityRegistrantName - d798315d8k.htm 7 d798315d8k.htm xoma-20240429.xsd xoma-20240429_def.xml xoma-20240429_lab.xml xoma-20240429_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d798315d8k.htm": { "nsprefix": "xoma", "nsuri": "http://www.xoma.com/20240429", "dts": { "inline": { "local": [ "d798315d8k.htm" ] }, "schema": { "local": [ "xoma-20240429.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "definitionLink": { "local": [ "xoma-20240429_def.xml" ] }, "labelLink": { "local": [ "xoma-20240429_lab.xml" ] }, "presentationLink": { "local": [ "xoma-20240429_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 3, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 4, "entityCount": 1, "segmentCount": 3, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-04-29_to_2024-04-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d798315d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-04-29_to_2024-04-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d798315d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "xoma_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20240429", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "xoma_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20240429", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.xoma.com//20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001193125-24-123689-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-123689-xbrl.zip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end XML 20 d798315d8k_htm.xml IDEA: XBRL DOCUMENT 0000791908 2024-04-29 2024-04-29 0000791908 us-gaap:CommonStockMember 2024-04-29 2024-04-29 0000791908 us-gaap:SeriesAPreferredStockMember 2024-04-29 2024-04-29 0000791908 us-gaap:SeriesBPreferredStockMember 2024-04-29 2024-04-29 XOMA Corp DE false 0000791908 8-K 2024-04-29 001-39801 52-2154066 2200 Powell Street Suite 310 Emeryville CA 94608 (510) 204-7200 false false false false Common Stock, $0.0075 par value XOMA NASDAQ 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share XOMAP NASDAQ Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share) XOMAO NASDAQ false